CompsDesk

Aclaris Therapeutics, Inc. (ACRS) — benchmarks from SEC filings

Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%

$8MRevenue FY2025
-58.2%Revenue growth
-975.9%Operating margin
-829.6%Net margin
-603.4%FCF margin
Fiscal yearRevenueOp marginNet margin
FY2025$8M-975.9%-829.6%
FY2024$19M-758.2%-705.5%
FY2023$31M-311.6%-283.1%
FY2022$30M-302.0%-292.1%
FY2021$7M-1327.1%-1344.0%

How does ACRS compare against its actual peer set?

The full CompsDesk Peer Benchmark Pack: 13 metrics × 5 years × your chosen peers, percentile placement, provenance for every number, board-ready PDF. One-off $249 — see a free sample pack first.

Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.